Titan Biotech (524717)
Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹576.8 |
| Market Cap | ₹476.65 Cr |
| P/E Ratio | 36.73 |
| ROCE | 16.9% |
| ROE | 17.92% |
| Dividend Yield | 0.17% |
| Profit Growth | 94.31% |
| Debt/Equity | — |
| Sales Growth | 47.62% |
| 52-Week Range | ₹171.4 — ₹576.8 |
| Sector | Chemicals & Petrochemicals |
| Book Value | ₹145.66 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Looking at Titan Biotech, I see a stock that has run from ₹88 to ₹577 in a year—a near seven-bagger. That alone makes me pause. But let's look beneath the surface. Sales grew 47.62% and profits 94.31%, with the latest quarter showing ₹57 Cr in sales and ₹9 Cr in net profit. That implies a net margin of roughly 15.8%, quite respectable for specialty chemicals. Return on equity is 17.92% and ROCE is 16.90%, both solid, suggesting management is deploying capital efficiently. The Piotroski F-score of 7/9 adds confidence in the underlying fundamentals.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer